Physician profile
Edward Rhim
NPI 1427180868
$1,084.02
in general payments reported to CMS, 2019-2025
14 companies · $63.97 in 2025
The $63.97 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.92 · 2022: $91.54 · 2023: $474 · 2024: $416 · 2025: $63.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $290.61 | 2022-2024 | Ffrct |
| Pfizer INC. | $134.90 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $111.53 | 2023-2024 | |
| Lantheus Medical Imaging, INC. | $105.26 | 2023-2024 | Definity |
| Amgen INC. | $79.89 | 2022-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $60.53 | 2023-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $57.18 | 2020-2024 | Farxiga |
| Boston Scientific Corporation | $48.50 | 2024-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.56 | 2023-2024 | Jardiance |
| Tactile Systems Technology INC | $44.70 | 2024 | Entre Plus, Flexitouch Plus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.79 | 2022-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $32.87 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $20.17 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $17.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Rhim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.